U.S. markets closed

Protalix BioTherapeutics, Inc. (PLX)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
2.0000-0.0500 (-2.44%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close2.0500
Open2.0400
Bid2.0000 x 1000
Ask2.0100 x 4000
Day's Range1.9300 - 2.0500
52 Week Range1.9300 - 7.0200
Volume3,207,642
Avg. Volume2,047,438
Market Cap90.766M
Beta (5Y Monthly)2.73
PE Ratio (TTM)N/A
EPS (TTM)-0.3930
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX

    NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (“Protalix” or the “Company”) (NYSE: PLX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Protalix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the c

  • PLX: BALANCE: Interim Analysis
    Zacks Small Cap Research

    PLX: BALANCE: Interim Analysis

    By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT BALANCE Interim Results On June 2, 2021, Protalix and development partner, Chiesi Global Rare Diseases, provided an update regarding clinical development of Protalix’ candidate pegunigalsidase alfa (PRX-102) and hosted a conference call and webcast the same morning to discuss results. Featured on the call was Dr. Ulrich Granzer

  • PLX: BALANCE: Interim Results
    Zacks Small Cap Research

    PLX: BALANCE: Interim Results

    By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT BALANCE Interim Results On June 2, 2021, Protalix (NYSE:PLX) and development partner, Chiesi Global Rare Diseases, provided an update regarding clinical development of Protalix’ candidate pegunigalsidase alfa (PRX-102) and hosted a conference call and webcast the same morning to discuss results. Featured on the call was Dr.